Discovering and validating unknown phospho-sites from p38 and HuR protein kinases in vitroby Phosphoproteomic and Bioinformatic tools
Tóm tắt
The mitogen activated protein kinase (MAPK) pathways are known to be deregulated in many human malignancies. Phosphopeptide identification of protein-kinases and site determination are major challenges in biomedical mass spectrometry (MS). P38 and HuR protein kinases have been reported extensively in the general principles of signalling pathways modulated by phosphorylation, mainly by molecular biology and western blotting techniques. Thus, although it has been demonstrated they are phosphorylated in different stress/stimuli conditions, the phosphopeptides and specific amino acids in which the phosphate groups are located in those protein kinases have not been shown completely. We have combined different resins: (a) IMAC (Immobilized Metal Affinity Capture), (b) TiO2 (Titanium dioxide) and (c) SIMAC (Sequential Elution from IMAC) to isolate phosphopeptides from p38 and HuR protein kinases in vitro. Different phosphopeptide MS strategies were carried out by the LTQ ion Trap mass spectrometer (Thermo): (a) Multistage activation (MSA) and (b) Neutral loss MS3 (DDNLMS3). In addition, Molecular Dynamics (MD) bioinformatic simulation has been applied in order to simulate, over a period of time, the effects of the presence of the extra phosphate group (and the associated negative charge) in the overall structure and behaviour of the protein HuR. This study is supported by the Declaration of Helsinki and subsequent ethical guidelines. The combination of these techniques allowed for: (1) The identification of 6 unknown phosphopeptides of these protein kinases. (2) Amino acid site assignments of the phosphate groups from each identified phosphopeptide, including manual validation by inspection of all the spectra. (3) The analyses of the phosphopeptides discovered were carried out in four triplicate experiments to avoid false positives getting high reproducibility in all the isolated phosphopeptides recovered from both protein kinases. (4) Computer simulation using MD techniques allowed us to get functional models of both structure and interactions of the previously mentioned phosphorylated kinases and the differences between their phosphorylated and un-phosphorylated forms. Many research studies are necessary to unfold the whole signalling network (human proteome), which is so important to advance in clinical research, especially in the cases of malignant diseases.
Tài liệu tham khảo
Han J, Sun P: The pathways to tumor suppression via route p38. Trends Biochem Sci. 2007, 32 (8): 364-371. 10.1016/j.tibs.2007.06.007. 2007
Lluis F, Perdiguero E, Nebreda AR, Munoz-Canoves P: Regulation of skeletal muscle gene expression by p38 MAP kinases. Trends Cell Biol. 2006, 16 (1): 36-44. 10.1016/j.tcb.2005.11.002. 2006
Zarubin T, Han J: Activation and signalling of the p38 MAP kinase pathway. Cell Res. 2005, 15 (1): 11-18. 10.1038/sj.cr.7290257. 2005
Cuenda A, Rousseau S: p38 MAP-kinases pathway regulation, function and role in human diseases. Biochim Biophys Acta. 2007, 1773 (8): 1358-1375. 10.1016/j.bbamcr.2007.03.010. 2007
Dolado I, Swat A, Ajenjo N, De Vita G, Cuadrado A, Nebreda AR: p38alpha MAP kinase as a sensor of reactive oxygen species in tumorigenesis. Cancer Cell. 2007, 11 (2): 191-205. 10.1016/j.ccr.2006.12.013. 2007
Cuadrado A, Nebreda AR: Mechanisms and functions of p38 MAPK signalling. Biochem J. 2010, 429 (3): 403-417. 10.1042/BJ20100323.
Kim HH, Gorospe M: Phosphorylated HuR shuttles in cycles. Cell Cycle. 2008, 7 (20): 3124-3126. 10.4161/cc.7.20.6884. 2008
Abdelmohsen K, Pullmann R, Lal A, Kim HH, Galban S, Yang X, Blethrow JD, Walker M, Shubert J, Gillespie DA, Furneaux H, Gorospe M: Phosphorylation of HuR by Chk2 regulates SIRT1 expression. Mol Cell. 2007, 25 (4): 543-557. 10.1016/j.molcel.2007.01.011. 2007b
Doller A, Huwiler A, Muller R, Radeke HH, Pfeilschifter J, Eberhardt W: Protein kinase C alpha-dependent phosphorylation of the mRNA-stabilizing factor HuR: implications for posttranscriptional regulation of cyclooxygenase-2. Mol Biol Cell. 2007, 18 (6): 2137-2148. 10.1091/mbc.E06-09-0850. 2007
Jin SH, Kim TI, Yang KM, Kim WH: Thalidomide destabilizes cyclooxygenase-2 mRNA by inhibiting p38 mitogen-activated protein kinase and cytoplasmic shuttling of HuR. Eur J Pharmacol. 2007, 558 (1-3): 14-20. 10.1016/j.ejphar.2006.11.060. 2007
Kim HH, Yang X, Kuwano Y, Gorospe M: Modification at HuR(S242) alters HuR localization and proliferative influence. Cell Cycle. 2008, 7 (21): 2008b
Kim HH, Abdelmohsen K, Lal A, Pullmann R, Yang X, Galban S, Srikantan S, Martindale JL, Blethrow J, Shokat KM, Gorospe M: Nuclear HuR accumulation through phosphorylation by Cdk1. Genes Dev. 2008, 22 (13): 1804-1815. 10.1101/gad.1645808. 2008a
Wang W, Furneaux H, Cheng H, Caldwell MC, Hutter D, Liu Y, Holbrook N, Gorospe M: HuR regulates p21 mRNA stabilization by UV light. Mol Cell Biol. 2000, 20 (3): 760-769. 10.1128/MCB.20.3.760-769.2000. 2000
Lafarga V, Cuadrado A, Lopez de Silanes I, Bengoechea R, Fernandez-Capetillo O, Nebreda AR: p38 Mitogen-activated protein kinase- and HuR-dependent stabilization of p21(Cip1) mRNA mediates the G(1)/S checkpoint. Mol Cell Biol. 2009, 29 (16): 4341-4351. 10.1128/MCB.00210-09. 2009
Kim HH, Abdelmohsen K, Gorospe M: Regulation of HuR by DNA Damage Response Kinases. J Nucleic Acids. 2010, 25: 2010-
Lopez de Silanes I, Fan J, Yang X, Zonderman AB, Potapova O, Pizer ES, Gorospe M: Role of the RNA-binding protein HuR in colon carcinogenesis. Oncogene. 2003, 22 (46): 7146-7154. 10.1038/sj.onc.1206862. 2003
Abdelmohsen K, Lal A, Kim HH, Gorospe M: Posttranscriptional orchestration of an anti-apoptotic program by HuR. Cell Cycle. 2007, 6 (11): 1288-1292. 10.4161/cc.6.11.4299. 2007a
Doller A, Pfeilschifter J, Eberhardt W: Signalling pathways regulating nucleo-cytoplasmic shuttling of the mRNA-binding protein HuR. Cell Signal. 2008, 20 (12): 2165-2173. 10.1016/j.cellsig.2008.05.007. 2008
Fernau NS, Fugmann D, Leyendecker M, Reimann K, Grether-Beck S, Galban S, Ale-Agha N, Krutmann J, Klotz LO: Role of HuR and p38MAPK in ultraviolet B-induced post-transcriptional regulation of COX-2 expression in the human keratinocyte cell line HaCaT. J Biol Chem. 2010, 285 (6): 3896-3904. 10.1074/jbc.M109.081430. 2010
Subbaramaiah K, Marmo TP, Dixon DA, Dannenberg AJ: Regulation of cyclooxgenase-2 mRNA stability by taxanes: evidence for involvement of p38, MAPKAPK-2, and HuR. J Biol Chem. 2003, 278 (39): 37637-37647. 10.1074/jbc.M301481200. 2003
Farooq F, Balabanian S, Liu X, Holcik M, MacKenzie A: p38 Mitogen-activated protein kinase stabilizes SMN mRNA through RNA binding protein HuR. Hum Mol Genet. 2009, 18 (21): 4035-4045. 10.1093/hmg/ddp352. 2009
Shi Y, Gaestel M: In the cellular garden of forking paths: how p38 MAPKs signal for downstream assistance. Biol Chem. 2002, 383 (10): 1519-1536. 10.1515/BC.2002.173. 20002
Thingholm TE, Larsen MR, Ingrell CR, Kassem M, Jensen ON: TiO(2)-based phosphoproteomic analysis of the plasma membrane and the effects of phosphatase inhibitor treatment. J Proteome Res. 2008, 7 (8): 3304-13. 10.1021/pr800099y. 2008
Thingholm TE, Jensen ON, Larsen MR: Enrichment and separation of mono- and multiply phosphorylated peptides using sequential elution from IMAC prior to mass spectrometric analysis. Methods Mol Biol. 2009, 527: 67-78. 10.1007/978-1-60327-834-8_6. (2009) Review
Ashman K, Lopez-Villar E: Phosphoproteomics and cancer research. Clin Transl Oncol. 2009, 11 (6): 356-62. 10.1007/s12094-009-0369-z. (2009) Review
Palmisano G, Thingholm TE: Strategies for quantitation of phosphoproteomic data. Expert Rev Proteomics. 2010, 7 (3): 439-56. 10.1586/epr.10.19. (2010) Review
López E, Matthiesen R, López I, Ashman K, Mendieta J, Wesselink JJ, Gómez-Puertas P, Ferreira A: Functional phosphoproteomics tools for current immunological disorders research. JOURNAL OF INTEGRATED OMICS. 2011, 1 (1): 1-16. [http://www.jiomics.com/]
Miller ML, Blom N: Kinase-specific prediction of protein phosphorylation sites. Methods Mol Biol. 2009, 527: 299-310. 10.1007/978-1-60327-834-8_22. 2009
Zhao X, León IR, Bak S, Mogensen M, Wrzesinski K, Højlund K, Jensen ON: Phosphoproteome analysis of functional mitochondria isolated from resting human muscle reveals extensive phosphorylation of inner membrane protein complexes and enzymes. Mol Cell Proteomics. 2011, 10 (1): M110.000299-10.1074/mcp.M110.000299. 2011
Larsen MR, Thingholm TE, Jensen ON, Roepstorff P, Jørgensen TJ: Highly selective enrichment of phosphorylated peptides from peptide mixtures using titanium dioxide microcolumns. Mol Cell Proteomics. 2005, 4 (7): 873-86. 10.1074/mcp.T500007-MCP200. 2005
Thingholm TE, Jørgensen TJ, Jensen ON, Larsen MR: Highly selective enrichment of phosphorylated peptides using titanium dioxide. Nat Protoc. 2006, 1 (4): 1929-35. 10.1038/nprot.2006.185. 2006
Nühse TS, Stensballe A, Jensen ON, Peck SC: Large-scale analysis of in vitro phosphorylated membrane proteins by immobilized metal ion affinity chromatography and mass spectrometry. Mol Cell Proteomics. 2003, 2 (11): 1234-43. 10.1074/mcp.T300006-MCP200.
Lee J, Xu Y, Chen Y, Sprung R, Kim SC, Xie S, Zhao Y: Mitochondrial phosphoproteome revealed by an improved IMAC method and MS/MS/MS. Mol Cell Proteomics. 2007, 6 (4): 669-76. 10.1074/mcp.M600218-MCP200. 2007
Thingholm TE, Jensen ON, Robinson PJ, Larsen MR: SIMAC (sequential elution from IMAC), a phosphoproteomics strategy for the rapid separation of monophosphorylated from multiply phosphorylated peptides. Mol Cell Proteomics. 2008, 7 (4): 661-71. 2008
Jensen SS, Larsen MR: Evaluation of the impact of some experimental procedures on different phosphopeptide enrichment techniques. Rapid Commun Mass Spectrom. 2007, 21 (22): 3635-45. 10.1002/rcm.3254. 2007
Mann M, Jensen ON: Proteomic analysis of post-translational modifications. Nat Biotechnol. 2003, 21 (3): 255-61. 10.1038/nbt0303-255. 2003
Gruhler A, Olsen JV, Mohammed S, Mortensen P, Faergeman NJ, Mann M, Jensen ON: Quantitative phosphoproteomics applied to the yeast pheromone signalling pathway. Mol Cell Proteomics. 2005, 4 (3): 310-27. 10.1074/mcp.M400219-MCP200. 2005
Thingholm TE, Jensen ON, Larsen MR: Analytical strategies for phosphoproteomics. Proteomics. 2009, 9 (6): 1451-68. 10.1002/pmic.200800454. (2009) Review
Patel SB, Cameron PM, O'Keefe SJ, Frantz-Wattley B, Thompson J, O'Neill EA, Tennis T, Liu L, Becker JW, Scapin G: The three-dimensional structure of MAP kinase p38beta: different features of the ATP-binding site in p38beta compared with p38alpha. Acta Crystallogr D Biol Crystallogr. 2009, 65 (Pt 8): 777-85. 2009
Benoit RM, Meisner N-C, Kallen J, Graff P, Hemmig R, Cèbel R, Ostermeier C, Widmer H, Auer M: The X-ray Crystal Structure of the First RNA Recognition Motif and Site-Directed Mutagenesis Suggest a Possible HuR Redox Sensing Mechanism. J Mol Biol. 2010, 397: 1231-1244. 10.1016/j.jmb.2010.02.043. 2010
Guex N, Diemand A, Peitsch MC: Protein modelling for all. Trends Biochem Sci. 1999, 24: 364-367. 10.1016/S0968-0004(99)01427-9. 1999
Peitsch MC: ProMod and Swiss-Model: Internet-based tools for automated comparative protein modelling. Biochem Soc Trans. 1996, 24: 274-279. 1996
Schwede T, Kopp J, Guex N, Peitsch MC: SWISS-MODEL: An automated protein homology-modeling server. Nucleic Acids Res. 2003, 31: 3381-3385. 10.1093/nar/gkg520. 2003
Case DA, Cheatham TE, Darden T, Gohlke H, Luo R, Merz KM, Onufriev A, Simmerling C, Wang B, Woods RJ: The Amber biomolecular simulation programs. J Comput Chem. 2005, 26: 1668-1688. 10.1002/jcc.20290. 2005
Mendieta J, Fuertes MA, Kunchitapatham R, Santa-María I, Moreno FJ, Alonso C, Gago F, Muñoz V, Avila J, Hernández F: Phosphorylation Modulates the Alpha Helical Structure and Polymerization of a Peptide from the Third Tau Microtubule-Binding Repeat. Biochim Biophys Acta. 2005, 1721: 16-26. 2005
Thingholm TE, Larsen MR, Ingrell CR, Kassem M, Jensen ON: TiO(2)-based phosphoproteomic analysis of the plasma membrane and the effects of phosphatase inhibitor treatment. J Proteome Res. 2008, 7 (8): 3304-13. 10.1021/pr800099y. 2008
Schroeder MJ, Shabanowitz J, Schwartz JC, Hunt DF, Coon JJ: A neutral loss activationmethod for improved phosphopeptide sequence analysis by quadrupole ion trap mass spectrometry. Anal Chem. 2004, 76: 3590-3598. 10.1021/ac0497104. 2004
Jiang X, Ye M, Han G, Dong X, Zou H: Classification filtering strategy to improve the coverage and sensitivity of phosphoproteome analysis. Anal Chem. 2010, 82 (14): 6168-75. 10.1021/ac100975t. (2010) 15
Villén J, Beausoleil SA, Gygi SP: Evaluation of the utility of neutral-loss-dependent MS3 strategies in large-scale phosphorylation analysis. Proteomics. 2008, 8 (21): 4444-52. 10.1002/pmic.200800283. 2008
Steen H, Küster B, Mann M: Quadrupole time-of-flight versus triple-quadrupole mass spectrometry for the determination of phosphopeptides by precursor ion scanning. J Mass Spectrom. 2001, 36 (7): 782-90. 10.1002/jms.174.
Steen H, Mann M: A new derivatization strategy for the analysis of phosphopeptides by precursor ion scanning in positive ion mode. J Am Soc Mass Spectrom. 2002, 13 (8): 996-1003. 10.1016/S1044-0305(02)00415-4.
Navajas R, Paradela A, Albar JP: Immobilized metal affinity chromatography/reversed-phase enrichment of phosphopeptides and analysis by CID/ETD tandem mass spectrometry. Methods Mol Biol. 2011, 681: 337-48. 10.1007/978-1-60761-913-0_18. 2011
Kleinnijenhuis AJ, Kjeldsen F, Kallipolitis B, Haselmann KF, Jensen ON: Analysis of histidine phosphorylation using tandem MS and ion-electron reactions. Anal Chem. 2007, 79 (19): 7450-6. 10.1021/ac0707838. 1
Stensballe A, Andersen S, Jensen ON: Characterization of phosphoproteins from electrophoretic gels by nanoscale Fe(III) affinity chromatography with off-line mass spectrometry analysis. Proteomics. 2001, 1 (2): 207-22. 10.1002/1615-9861(200102)1:2<207::AID-PROT207>3.0.CO;2-3.
Schroeder MJ, Webb DJ, Shabanowitz J, Horwitz AF, Hunt DF: Methods for the detection of paxillin post-translational modifications and interacting proteins by mass spectrometry. J Proteome Res. 2005, 4 (5): 1832-41. 10.1021/pr0502020.
Syka JE, Coon JJ, Schroeder MJ, Shabanowitz J, Hunt DF: Peptide and protein sequence analysis by electron transfer dissociation mass spectrometry. Proc Natl Acad Sci USA. 2004, 101 (26): 9528-33. 10.1073/pnas.0402700101. 29
Thingholm TE, Jensen ON, Larsen MR: Enrichment and separation of mono- and multiply phosphorylated peptides using sequential elution from IMAC prior to mass spectrometric analysis. Methods Mol Biol. 2009, 527: 67-78. 10.1007/978-1-60327-834-8_6. 2009
Meisner NC, Hintersteiner M, Mueller K, Bauer R, Seifert JM, Naegeli HU, Ottl J, Oberer L, Guenat C, Moss S, Harrer N, Woisetschlaeger M, Buehler C, Uhl V, Auer M: Identification and mechanistic characterization of low-molecular-weight inhibitors for HuR. Nat Chem Biol. 2007, 3: 508-515. 10.1038/nchembio.2007.14.
Besnard A, Galan-Rodriguez B, Vanhoutte P, Caboche J: Elk-1 a transcription factor with multiple facets in the brain. Front Neurosci. 2011, 5: 35-16
López E, López I, Ferreira A, Sequí J: Clinical and Technical Phosphoproteomic Research. Proteome Sci. 2011, 9 (1): 27-10.1186/1477-5956-9-27. 2
Kim J-E, Tannenbaum SR, White FM: Global phosphoproteome of HT-29 human colon adenocarcinoma cells. J Proteome Res. 2007, 4: 1339-1346.